Lilly's Foundayo Beats Novo's Ozempic Pill in Diabetes Analysis
LLY sits 66% above its 52-week low of $716.078.
Summary
Lilly released an indirect comparison showing its oral obesity drug Foundayo at 17.2 mg provides 1.5% to 2.4% greater weight loss and 0.3% to 0.6% larger A1C reductions than Novo Nordisk's 25 mg oral semaglutide in type 2 diabetes patients. The analysis uses data from two prior late-stage studies, not a head-to-head trial. Novo's 25 mg dose is not yet approved in the US, with an FDA decision expected by end of 2026. This strengthens Lilly's competitive positioning in the GLP-1 market, though the comparison is in diabetes, not obesity, and Novo disputes the relevance. The news follows Lilly's Q2 beat and FDA approval of Foundayo, adding a new data point in the ongoing rivalry.
At the time of this announcement, LLY was trading at $1,185.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $716.08 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.